We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

10 hedge funds and large institutions have $79.7K invested in Adaptimmune Therapeutics in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

15.26% less ownership

Funds ownership: 15.88% → 0.63% (-15%)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

82% less funds holding

Funds holding: 55 → 10 (-45)

98% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 46

99% less capital invested

Capital invested by funds: $5.47M → $79.7K (-$5.39M)

Holders
10
Holders Change
-45
Holders Change %
-81.82%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
4
Closed
46
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
+$34.1K
2
JAIC
Josh Arnold Investment Consultant
Minnesota
+$2.72K
3
Simplex Trading
Simplex Trading
Illinois
+$840

Top Sellers

Rank Fund Capital Flow
1
LFCM
Long Focus Capital Management
Puerto Rico
-$2.42M
2
UBS Group
UBS Group
Switzerland
-$867K
3
Renaissance Technologies
Renaissance Technologies
New York
-$527K
4
Morgan Stanley
Morgan Stanley
New York
-$477K
5
Jane Street
Jane Street
New York
-$365K
Name Holding Trade Value Shares
Change 		Change in
Stake
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$6.91K -53,186 Closed
Northern Trust
27
Northern Trust
Illinois
– -$6.32K -48,584 Closed
Wealth Enhancement Advisory Services
28
Wealth Enhancement Advisory Services
Minnesota
– -$5.66K -40,816 Closed
BlackRock
29
BlackRock
New York
– -$4.98K -38,296 Closed
CAP
30
Columbia Advisory Partners
Washington
– -$4.78K -36,730 Closed
SQA
31
Simon Quick Advisors
New Jersey
– -$3.9K -30,000 Closed
SG Americas Securities
32
SG Americas Securities
New York
– -$4K -27,497 Closed
Raymond James Financial
33
Raymond James Financial
Florida
– -$3.28K -25,261 Closed
PWM
34
Prosperity Wealth Management
California
– -$2.5K -19,227 Closed
SG
35
StoneX Group
New York
– -$1.96K -15,040 Closed
TCM
36
Traynor Capital Management
Pennsylvania
– -$1.95K -15,000 Closed
Goldman Sachs
37
Goldman Sachs
New York
– -$1.6K -12,320 Closed
Rockefeller Capital Management
38
Rockefeller Capital Management
New York
– -$1.58K -12,166 Closed
IA
39
IFG Advisory
Georgia
– -$1.52K -11,725 Closed
KCM
40
Kornitzer Capital Management
Kansas
– -$1.3K -10,000 Closed
Wells Fargo
41
Wells Fargo
California
– -$351 -2,700 Closed
Citigroup
42
Citigroup
New York
– -$348 -2,679 Closed
Osaic Holdings
43
Osaic Holdings
Arizona
– -$198 -2,058 Closed
TRCT
44
Tower Research Capital (TRC)
New York
– -$91 -700 Closed
WSFS
45
Wilmington Savings Fund Society
Delaware
– -$79 -604 Closed
HWM
46
HighMark Wealth Management
Minnesota
– -$37 -287 Closed
PA
47
Parallel Advisors
California
– -$33 -250 Closed
XSC
48
X-Square Capital
Puerto Rico
– -$29 -214 -2%
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
– -$28 -213 Closed
ASN
50
Advisory Services Network
Georgia
– -$16 -125 Closed
1
2
3

ADAP Hedge Fund Activity: Q4 2025 in Review

10 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2025, worth a combined $79.7K — down 99% from $5.47M a quarter earlier.

Sellers outnumbered buyers: 46 funds closed out of ADAP and 1 opened new positions — a net loss of 45 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was XTX Topco, adding an estimated $34.1K. The largest seller was Long Focus Capital Management, exiting entirely with an estimated $2.42M sold.

  • 10 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2025, down from 55 in Q3 2025.
  • Funds reported $79.7K of Adaptimmune Therapeutics stock for Q4 2025, down 99% quarter-over-quarter.
  • 1 fund opened new Adaptimmune Therapeutics positions in Q4 2025 and 46 closed out, a net change of -45 holders.
  • The largest Adaptimmune Therapeutics buyer in Q4 2025 was XTX Topco, an estimated $34.1K added.
  • The largest Adaptimmune Therapeutics seller in Q4 2025 was Long Focus Capital Management, an estimated $2.42M sold.

Based on aggregated 13F filings for Q4 2025.